Wednesday, October 3, 2012

Abraxane (nab-paclitaxel) meets primary endpoint in Phase 3 trial in Metastatic Melanoma - Competiton for Ipilimumab on the anvil

Metastatic Melanoma space is expected to get a lot more competitive as we might see another meaningful player. Celgene has reported that nab-paclitaxel or Abraxane has met the primary endpoint in improving Progression free survival when compared to dacarbazine in metastatic melanoma patients who have not received prior chemotherapy. The detailed data will be announced at Society for Melanoma Research meeting in Los Angeles in November.
In a Phase 2 study combining Abraxane with bevacizumab, the combination showed a median overall survival of 15.6 months, which is the best so far that has been observed with any agent. Even BMY's ipilimumab which was recently approved and is being widely used is associated with a median OS of less than 12 months.